Rigel Pharmaceuticals, Inc.  

(Public, NASDAQ:RIGL)   Watch this stock  
Find more results for R. Keith Elliott
3.05
-0.09 (-2.87%)
Jul 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.00 - 3.14
52 week 1.56 - 5.20
Open 3.14
Vol / Avg. 444,507.00/669,783.00
Mkt cap 268.84M
P/E     -
Div/yield     -
EPS -0.99
Shares 88.14M
Beta 1.38
Inst. own 88%
Aug 3, 2015
Q2 2015 Rigel Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 3, 2015
Rigel Pharmaceuticals Inc at Jefferies Global Healthcare Conference
May 7, 2015
Q1 2015 Rigel Pharmaceuticals Inc Earnings Call - Webcast
May 7, 2015
Q1 2015 Rigel Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -835.31% -1101.91%
Operating margin -837.51% -1106.05%
EBITD margin - -964.70%
Return on average assets -45.63% -47.82%
Return on average equity -60.71% -54.03%
Employees 127 -
CDP Score - -

Address

1180 Veterans Blvd
SOUTH SAN FRANCISCO, CA 94080-1985
United States - Map
+1-650-6241100 (Phone)
+1-650-6241101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company discovers and develops small-molecule drugs for the treatment of inflammatory and autoimmune diseases, immuno-oncology related diseases, and muscle disorders. Its research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. It has various product candidates in development: fostamatinib; R348; two oncology product candidates, and two preclinical programs. Fostamatinib is an oral spleen tyrosine kinase (SYK) inhibitor. R348 is a topical janus kinase (JAK)/SYK inhibitor. It is conducting research in the disease areas of inflammation/immunology and muscle wasting/muscle endurance.

Officers and directors

Raul R. Rodriguez President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Ryan D. Maynard Chief Financial Officer and Executive Vice President
Age: 45
Bio & Compensation  - Reuters
Dolly A. Vance Executive Vice President, Corporate Affairs, General Counsel and Corporate Secretary
Age: 50
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Donald G. Payan M.D. Executive Vice President, President - Discovery and Research, Director
Age: 66
Bio & Compensation  - Reuters
Elliott B. Grossbard M.D. Executive Vice President and Chief Medical Officer
Age: 67
Bio & Compensation  - Reuters
Keith A. Katkin Director
Age: 43
Bio & Compensation  - Reuters
Bradford S. Goodwin Independent Director
Age: 60
Bio & Compensation  - Reuters
Gary A. Lyons Independent Director
Age: 64
Bio & Compensation  - Reuters
Walter H. Moos Ph.D. Independent Director
Age: 60
Bio & Compensation  - Reuters
Peter S. Ringrose Ph.D. Independent Director
Age: 69
Bio & Compensation  - Reuters